As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.
|Articles|July 1, 2007
- Volume 0 0
ADVANCIS CHANGES ITS CORPORATE NAME
Advertisement
Advancis Pharmaceutical Corp has changed its corporate name to Middlebrook Pharmaceuticals Inc. The company is the supplier of cephalexin (Keflex) capsules.
MiddleBrook Pharmaceuticals is a company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease.
In May 2007, the FDA accepted for review MiddleBrook?s new drug application for Amoxicillin PULSYS, a once-daily pulsatile-release formulation of amoxicillin for oral administration.
Articles in this issue
over 19 years ago
pharmacy TECHNOLOGY newsover 19 years ago
pharmacy TECHNOLOGY productsover 19 years ago
health-systems PRODUCT newsover 19 years ago
generic times product newsover 19 years ago
can you READ these Rxs?over 19 years ago
A closer look at new FDA actionsover 19 years ago
can you READ these Rxs?over 19 years ago
compounding HOTLINEover 19 years ago
Is There Science in Quality?over 19 years ago
Vaccines: Are You Protected?Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Value of Self-Monitoring Blood Glucose Tools in Preventing and Reducing Prediabetes and Diabetes-Related Complications
2
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
3
Patients Report Early, Sustained Functional Gains With First-Line Zongertinib in HER2-Mutant NSCLC
4
What Different Communities Taught Me About Patient Care
5